Payment overview · 2025
General Payments
$76,885.61
233 reported records · 37 companies
Healthcare provider profile · identity verified
Nassir A Azimi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · LA MESA, CA · NPI 1366438764
Verified facts
What the public records show
CMS Open Payments records show Nassir A Azimi, M.D. received $76,885.61 in general payments during 2025 across 233 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 79.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Nexletol, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60,956.51 | 79.3% | 77 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $10,266.21 | 13.3% | 8 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $720.24 | 0.9% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $695.31 | 0.9% | 17 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $450.06 | 0.6% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $354.09 | 0.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $341.92 | 0.4% | 13 | 2025 |
| AOP Health US, LLC | Unresolved — no canonical attribution shown | $270.40 | 0.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $243.64 | 0.3% | 14 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $231.72 | 0.3% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $223.03 | 0.3% | 3 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $197.52 | 0.3% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $174.90 | 0.2% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $157.54 | 0.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.22 | 0.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $135.70 | 0.2% | 3 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $129.27 | 0.2% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $125.00 | 0.2% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $122.24 | 0.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $112.61 | 0.1% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $106.05 | 0.1% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$94.70 | 0.1% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $75.54 | 0.1% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $71.00 | 0.1% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $68.24 | 0.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $65.53 | 0.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.67 | 0.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.91 | 0.1% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $45.54 | 0.1% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.20 | 0.1% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $30.13 | 0.0% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.66 | 0.0% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $24.64 | 0.0% | 1 | 2025 |
| AltaThera Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $24.13 | 0.0% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $22.79 | 0.0% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $20.48 | 0.0% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $19.27 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,128.00 | 14 |
| Food and Beverage | $8,198.50 | 202 |
| Consulting Fee | $6,507.00 | 1 |
| Travel and Lodging | $5,052.11 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $53,964.67 | 74 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $10,266.21 | 8 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $720.24 | 19 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $341.92 | 13 | 2025 |
Source payment records
|
|||||
| Rapiblyk Normalized: rapiblyk |
Drug | AOP Health US, LLC | $270.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $237.39 | 8 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $231.72 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $229.10 | 11 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $197.52 | 3 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $182.19 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $174.90 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $162.42 | 10 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $155.55 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $143.55 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $135.70 | 3 | 2025 |
Source payment records
|
|||||
| GIAPREZA Normalized: giapreza |
Drug | La Jolla Pharmaceutical Company | $129.27 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $124.94 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $122.24 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $121.36 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $121.36 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $112.61 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $112.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $110.88 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $106.05 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $101.89 | 5 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $98.24 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $75.54 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $71.37 | 3 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $68.24 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $65.53 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.67 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.67 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.78 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $47.91 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Volara System Normalized: hillrom volara system |
Device | Baxter Healthcare | $46.61 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $45.54 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $38.20 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $32.60 | 1 | 2025 |
Source payment records
|
|||||
| ANDEXXA Normalized: andexxa |
Biological | AstraZeneca Pharmaceuticals LP | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| Sotalol Hydrochloride Normalized: sotalol hydrochloride |
Drug | AltaThera Pharmaceuticals LLC | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| JUXTAPID Normalized: juxtapid |
Drug | Chiesi USA, Inc. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 244 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 81 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
195 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 23 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
244 | 67 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
244 | 67 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1004 | 279 |
| Entresto | Sacubitril/Valsartan | 728 | 168 |
| Carvedilol | Carvedilol | 575 | 155 |
| Losartan Potassium | Losartan Potassium | 517 | 161 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 357 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 352 | 99 |
| Xarelto | Rivaroxaban | 308 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 301 | 96 |
| Eliquis | Apixaban | 244 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 228 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 62 |
| Spironolactone | Spironolactone | 209 | 60 |
| Brilinta | Ticagrelor | 195 | 43 |
| Amiodarone Hcl | Amiodarone Hcl | 176 | 50 |
| Nitroglycerin | Nitroglycerin | 172 | 87 |
| Lisinopril | Lisinopril | 168 | 49 |
| Furosemide | Furosemide | 161 | 55 |
| Ezetimibe | Ezetimibe | 160 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 32 |
| Valsartan | Valsartan | 104 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 27 |
| Multaq | Dronedarone Hcl | 90 | 22 |
| Vascepa | Icosapent Ethyl | 89 | 20 |
| Prasugrel Hcl | Prasugrel Hcl | 86 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 82 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 22 |
| Jardiance | Empagliflozin | 81 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 20 |
| Ranolazine Er | Ranolazine | 69 | 21 |
| Ozempic | Semaglutide | 56 | 14 |
| Farxiga | Dapagliflozin Propanediol | 54 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 12 |
| Simvastatin | Simvastatin | 48 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 44 | 15 |
| Metformin Hcl | Metformin Hcl | 41 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 13 |
| Omeprazole | Omeprazole | 39 | 12 |
| Digoxin | Digoxin | 37 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 33 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Eplerenone | Eplerenone | 30 | suppressed |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 29 | 14 |
| Repatha Syringe | Evolocumab | 29 | 11 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Nexletol | Bempedoic Acid | 28 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Invokana | Canagliflozin | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Niacin Er | Niacin | 21 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Wegovy | Semaglutide | 16 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Inpefa | Sotagliflozin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76,885.61 · 233 records | Bayer Healthcare Pharmaceuticals Inc. | AFREZZA, AMVUTTRA, ANDEXXA, AVEIR, Assure WCD, Attruby, BREZTRI, Barostim Neo System, CAMZYOS, DUPIXENT, EDARBI, ELIQUIS, ESPRIT, EVKEEZA, FARXIGA, FUROSCIX, GIAPREZA, Hillrom - Cardiac Ambulatory Monitor, Hillrom - Volara System, INJECTAFER, INSPIRE, JARDIANCE, JUXTAPID, Kerendia, LOKELMA, LifeVest, MOUNJARO, NEXLETOL, NUCALA, Nayzilam, ONYX FRONTIER, OPSUMIT, Ozempic, PERCLOSE PROSTYLE, REPATHA, Rapiblyk, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, SYMPLICITY G3, Sotalol Hydrochloride, TEZSPIRE, UPTRAVI, VERQUVO, VOWST, VYNDAQEL, WAINUA, WINREVAIR, WatchPATONE, XIENCE SKYPOINT, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error